Does liposomal vitamin C really work?

Nine out of ten published trials found that liposomal vitamin C puts more of the vitamin into your bloodstream — and only two of those ten checked whether it made any difference to your health.

That gap is the honest answer to the question. The 2025 scoping review that pooled every published trial confirms the absorption advantage is real and repeatable, with area-under-the-curve values running 1.3 to 7.2 times higher than standard vitamin C. What it also confirms is that almost nobody has tested what happens next.

What This Article Covers

• The short answer
• What the absorption evidence actually shows
• Why the numbers range from 30% to 620%
• The gap nobody puts on the label
• Who paid for the research
• Does "liposomal" on a label mean anything?
• When the format actually matters
• Bio Absorb Nutraceuticals' approach
• Frequently asked questions
• The bottom line
• Research references

The Short Answer

"Does it work?" is really two questions, and the research answers them differently. Does more vitamin C reach your bloodstream? Yes — that is about as settled as supplement science gets, confirmed across ten trials using doses from 150 mg to 10 g. Does that extra vitamin C then do more for your health? That has scarcely been tested.

The honest position is that liposomal delivery solves a measurement problem convincingly and a health problem unconvincingly. Higher blood levels are a means, not an end. Of the ten trials in the 2025 review, only two looked at cellular uptake and only two looked at biological effects — so the chain from "more absorbed" to "better off" has two strong links and one that has barely been examined.

This is not the same question as whether you should switch. That depends on your dose, your budget and your tolerance, and we cover it separately in is liposomal vitamin C better? This page is about how good the evidence is.

What the Absorption Evidence Actually Shows

The strongest single source is a 2025 scoping review by vitamin C researcher Anitra Carr, which screened 321 studies and included the 10 that directly compared liposomal with non-liposomal vitamin C in people. Seven used randomised crossover designs, one used parallel groups and two were not randomised. Nine of the ten found higher bioavailability for the liposomal form.

The individual trials give a sense of the scale. In a randomised double-blind crossover trial in 27 adults given 500 mg, the liposomal form produced 27% higher peak plasma vitamin C and 21% greater total exposure over 24 hours. A separate crossover trial in 24 adults at a 1 g dose reported a larger gap, with peak concentration of 5.2 versus 1.2 mg/dL and half-life extended from 12.4 to 19 hours.

Notice that last figure. Part of what liposomal delivery does is keep vitamin C in circulation longer rather than simply push more of it in at once — which is why the AUC gap is often wider than the peak-concentration gap. For the underlying mechanism, see our guide to liposomal vitamin C.

Why the Numbers Range From 30% to 620%

A 1.3-to-7.2-fold range is enormous, and the reason is not measurement noise. It is that "liposomal" describes a category, not a product. The trials used doses from 0.15 to 10 g and sampling windows from 4 to 24 hours, on formulations built in completely different ways.

The top of that range comes from the most heavily engineered product in the set, not from liposomes as such:

• A fenugreek-galactomannan-reinforced powder tested in 14 people reached 282 µM peak concentration against 52 µM for the unformulated control — the outlier that sets the 7.2× ceiling.
• A registered crossover trial of a spray-dried liposomal powder in 10 adults at 1000 mg found a 30% AUC increase — far closer to the floor.
• Trial sizes across the ten trials run from 5 to 27 participants, which is small for pharmacokinetic work.

The practical consequence is that a headline multiple taken from one trial tells you almost nothing about a different product. Anyone quoting a single figure such as "up to 10 times better absorbed" is quoting the best result in the literature as though it were the typical one.

The Gap Nobody Puts on the Label

Here is the finding that rarely makes it into marketing copy. The 2025 review states plainly that none of the ten trials assessed how much vitamin C was eliminated, so it is not known whether the liposomal-to-standard ratio in urine matches the ratio measured in blood. Higher plasma readings could partly reflect vitamin C in transit to the kidneys.

The one trial that did measure a function is the most instructive in the set. Researchers gave 11 adults 4 g of vitamin C in four ways — placebo, standard oral, liposomal oral and intravenous — then induced 20 minutes of forearm ischemia to generate oxidative stress. Liposomal produced higher circulating vitamin C than standard oral, but protection against oxidative stress was similar to the protection from unencapsulated vitamin C.

One small trial does not settle the matter, and it tested a single endpoint at a dose twice the 2000 mg upper limit. But it is the closest thing to a direct test that exists, and it did not find the advantage the absorption data would predict. For what vitamin C does deliver on measured outcomes, see vitamin C for colds and flu.

Who Paid for the Research

The UK's Committee on Toxicity reviewed this same literature and raised a structural concern: most studies of novel supplement formulations are conducted or commissioned by manufacturers, and negative results are less likely to be submitted for publication. The Committee expects the published record to lean positive as a result.

That is visible in the trials cited on this page. The 27-person 500 mg trial was funded by the company that makes the tested ingredient, and the 14-person galactomannan study came from the developer's own research centre. Both are peer-reviewed and neither is disqualified by its funding — but a reader weighing a 1.3-to-7.2-fold claim should know that most of the underlying work was paid for by people selling the format.

The 11-person oxidative stress trial is worth noting for the opposite reason. One of its authors was affiliated with liposomal manufacturers, and it still reported no functional advantage — which makes that null result harder to dismiss, not easier.

Does "Liposomal" on a Label Mean Anything?

Legally, very little. The Committee on Toxicity found that many products marketed as liposomal are not rigorously characterised in physicochemical terms, and that products making precise absorption claims generally give no reference and no clear comparison point.

This matters more than the 1.3-to-7.2 range does. A trial result belongs to the exact formulation tested — its phospholipid source, vesicle size, encapsulation efficiency and stability through stomach acid. Vesicle sizes in the published research span 20 nanometres to over 1 micrometre, a difference of more than fiftyfold. Two products can both say "liposomal" and behave nothing alike.

What you can reasonably check is whether a manufacturer is willing to show its work: third-party testing of every batch, a certificate of analysis on request, and a clear statement of what the liposome is made from. Those are verifiable. A bioavailability multiple printed on a carton usually is not.

When the Format Actually Matters

The format can only fix a problem that exists, and at low doses there is not much of one. The foundational NIH pharmacokinetic work found that bioavailability was complete for a single 200 mg dose and only declined from 500 mg upward, with the excess excreted. The NIH's current guidance puts absorption at roughly 70–90% at intakes of 30 to 180 mg a day.

So the answer shifts with the dose you are actually taking:

• At or below about 200 mg a day, standard vitamin C is essentially fully absorbed and there is little for a delivery system to improve.
• Between 500 and 1000 mg, absorption efficiency falls and the liposomal evidence is strongest — most of the trials sit in this range.
• Above 2000 mg a day, the tolerable upper intake level, dose questions matter more than format questions. See high-dose vitamin C.

There is a second wrinkle. The same NIH work found that neutrophils, monocytes and lymphocytes saturate at around 100 mg a day and hold concentrations at least 14 times higher than plasma. Immune cells fill up early, which is worth knowing before buying absorption for immune reasons. Our guide to vitamin C dosage covers the numbers in full.

Bio Absorb Nutraceuticals' Approach

Bio Absorb Nutraceuticals takes the position this article argues for: the absorption case for liposomal delivery is solid, the outcome case is still open, and the sensible response is to be checkable rather than to make bigger claims than the evidence supports.

Their Liposomal Vitamin C Liquid 1000mg (Corn-Free) and Liposomal Vitamin C Capsules 1000mg (Corn-Free) share one formulation across two formats. The liquid has a natural orange flavour and mixes into water or juice; the capsules need no refrigeration and travel well. Both are verified corn-free — which matters because ascorbic acid is conventionally fermented from corn — along with non-GMO, gluten-free, nut-free, dairy-free and vegan.

On the verifiability point raised above: every batch is third-party tested, and manufacturing is GMP-certified and based in Canada. Those are claims a reader can ask to see evidence for, which is the distinction that matters when a category is full of unreferenced absorption multiples. Products are backed by a money-back guarantee. See current pricing and serving details for either format.

What you will not find is a bioavailability multiple printed on the label. Given how much those numbers vary between formulations, quoting one would tell you less than it appears to.

Frequently Asked Questions

Is liposomal vitamin C a scam?

No. The absorption advantage is real and has been reproduced in nine of ten published trials, with AUC values 1.3 to 7.2 times higher than standard vitamin C. What is unsupported is the leap from that to specific health claims, since only two of those ten trials measured any biological effect at all.

Does better absorption mean better health outcomes?

That has not been demonstrated. The one trial that tested a functional endpoint found that at a 4 g dose, liposomal vitamin C protected against oxidative stress about as well as plain vitamin C despite producing higher blood levels. More research on outcomes rather than blood levels is what the field is waiting for.

Why do brands claim such different absorption numbers?

Because they are quoting different trials of different formulations. The published range spans a 30% AUC increase at one end and a roughly sevenfold increase at the other, and the largest multiples came from heavily engineered powders rather than conventional liposomes. A figure from one product does not transfer to another.

Is liposomal vitamin C worth it at a low dose?

Probably not. Absorption is complete at a single 200 mg dose and only begins to decline from 500 mg upward, so below roughly 400 mg a day there is little inefficiency for the format to correct. The evidence is strongest in the 500–1000 mg range.

Is liposomal vitamin C gentler on the stomach?

It may be, though this is an inference rather than a tested result. The 2000 mg upper intake level is based largely on the gut symptoms caused by unabsorbed vitamin C, so a form that leaves less unabsorbed could plausibly be better tolerated. See the side effects of liposomal vitamin C for the detail.

Should I take vitamin C at all if I am not deficient?

That is a decision for you and your doctor. Regular supplementation did not reduce how often adults caught colds across 29 comparisons covering 11,306 participants, though across a separate set of 31 comparisons covering 9,745 episodes it shortened them by about 8%. Anyone with kidney disease, haemochromatosis or on regular medication should speak to a physician first.

The Bottom Line

Liposomal vitamin C does what it says on the absorption question — nine of ten trials agree — and has barely been tested on the questions most people actually care about. If you are taking 500 mg or more a day, the format has something to offer; below that, it is solving a problem you do not have. Compare the liquid and capsule formats and decide based on your dose, not on a multiple printed on a box.

Research References

1. Do Liposomal Vitamin C Formulations Have Improved Bioavailability? A Scoping Review Identifying Future Research Directions. Basic & Clinical Pharmacology & Toxicology, Vol. 137, Issue 1 (2025). Screened 321 studies and included 10; nine showed higher bioavailability for liposomal vitamin C (1.2–5.4× Cmax, 1.3–7.2× AUC), while none assessed elimination and only two assessed biological effects.
2. Liposomal delivery enhances absorption of vitamin C into plasma and leukocytes: a double-blind, placebo-controlled, randomized trial. European Journal of Nutrition, Vol. 63 (2024). In 27 adults at a 500 mg dose, liposomal vitamin C produced 27% higher plasma peak concentration and 21% greater 24-hour exposure than standard vitamin C.
3. Evaluation and clinical comparison studies on liposomal and non-liposomal ascorbic acid (vitamin C) and their enhanced bioavailability. Journal of Liposome Research, Vol. 31, Issue 4 (2021), pp. 356–364. In 24 fasting adults at a 1 g dose, the liposomal form reached a peak concentration of 5.2 versus 1.2 mg/dL, raised AUC0–24h to 55.9 from 31.5 mg·h/dL, and extended half-life from 12.4 to 19 hours.
4. Liposomal-encapsulated Ascorbic Acid: Influence on Vitamin C Bioavailability and Capacity to Protect Against Ischemia-Reperfusion Injury. Nutrition and Metabolic Insights, Vol. 9 (2016). In 11 adults at 4 g, liposomal delivery raised circulating vitamin C above standard oral but protection against oxidative stress was similar to unencapsulated vitamin C.
5. Surface-engineered liposomal particles of calcium ascorbate with fenugreek galactomannan enhanced the oral bioavailability of ascorbic acid. RSC Advances, Vol. 11, Issue 60 (2021). In 14 volunteers, the engineered formulation reached 282 µM peak concentration against 52 µM for unformulated vitamin C — the source of the upper end of the published range.
6. Bioavailability of Liposomal Vitamin C in Powder Form: A Randomized, Double-Blind, Cross-Over Trial. Applied Sciences, Vol. 14, Issue 17 (2024). In 10 adults at 1000 mg, a spray-dried liposomal powder produced a 30% increase in AUC over non-liposomal vitamin C.
7. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proceedings of the National Academy of Sciences, Vol. 93, Issue 8 (1996). Found bioavailability complete at a single 200 mg dose and declining from 500 mg upward, with immune cells saturating at 100 mg daily at concentrations at least 14-fold above plasma.
8. Vitamin C for preventing and treating the common cold. Cochrane Database of Systematic Reviews, Issue 1 (2013). Across 29 comparisons and 11,306 participants, regular supplementation did not reduce cold incidence; across a separate 31 comparisons and 9,745 episodes it shortened duration by 8% in adults.
9. Novel formulations of supplement compounds designed to increase oral bioavailability. UK Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment (2025). Concluded that reporting bias likely skews this literature positive, and that products marketed as liposomal are frequently not rigorously characterised.
10. Vitamin C — Fact Sheet for Health Professionals. National Institutes of Health, Office of Dietary Supplements (2025). States that approximately 70–90% of vitamin C is absorbed at intakes of 30–180 mg daily, with absorption falling at higher doses, and sets the tolerable upper intake level at 2000 mg daily.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.